Tianjin TEDA Biomedical Engineering Company Limited (TEDA Biomedical) reported that shareholders approved a key special resolution at the 24 September 2026 Extraordinary General Meeting (EGM), granting the Board discretionary authority to issue new shares representing up to 50% of the company’s existing issued share capital within the next three years.
The proposal was carried by poll, receiving 482.72 million votes in favour (72.57%) against 182.50 million votes (27.43%), out of a total 665.22 million shares voted. Voter turnout stood at roughly 31.2% of TEDA Biomedical’s 2.13 billion issued shares.
Under the newly added Articles of Association clauses, the Board may execute equity issuances without further shareholder approval unless the consideration involves non-monetary assets, in which case a separate shareholder resolution is required. Any Board decision under this mandate must secure support from at least two-thirds of all directors and comply with listing-venue securities regulations.
No shareholders were obliged to abstain, and none indicated an intention to vote against or abstain prior to the meeting. All resolutions in the EGM notice dated 7 September 2026 were passed.
Executive Director Yang Zeng, Non-Executive Directors Xia Alan Zhe and Wang Lei, and Independent Non-Executive Directors Tu Xiangzhen and Chen Jiang attended the meeting. Peking Certified Public Accountants served as the independent scrutineer for the vote count.
TEDA Biomedical’s announcement will remain available on the Hong Kong Stock Exchange and company websites for seven days from posting.